3. 3
Why do we need to talk?
Perspective
What is a meaningful
endpoint?
Value
Coordination
Disease
Understanding
Research
Breakthroughs
Ensuring
Access
Diagnosis
4. 4
IRDiC
International Rare
Disease Research
Consortium
Working to bring
200 new rare
disease treatments
by 2020
International with a
long history of
Canadian
involvement
Adapt-Smart
Private-public
consortium
Address drivers,
opportunities and
obstacles to
adaptive pathways
for earlier access
Green Park
Collaborative
Multi-stakeholder
forum looking at
ways to incorporate
real world data into
development
EUPATI
IMI initiative
involving 33
institutions
Educate patients on
drug development
and registration
Existing Collaborations
5. 5
• Brings all players to the table
• Work towards a common
understanding
• Build a sustainable solution
• Regulatory framework that
provides a common reference
point
Benefits For Canada
6. 6
• A single integrated
message
• Highlights the scientific
expertise found in
Canada
• Brings Canadian biotech
to the forefront
• Provides a potential
roadmap for other
countries
International